Portfolio Tracker
Dein Depot in Echtzeit – Kurse, Renditeanalyse und Dividendenplaner an einem Ort.
Anzeige

Pipeline update and final results for the year ended 31 January 2024 06.06.2024, 14:34 Uhr von EQS News Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
Kostenlose Aktienchance per SMS Ausgewählte Trading-Einschätzungen aufs Handy.

JP Jenkins Ltd
Pipeline update and final results for the year ended 31 January 2024

06-Jun-2024 / 13:34 GMT/BST
The issuer is solely responsible for the content of this announcement.


6th June 2024

ISIN: GB00B2823H99

JPJ:ETX

 

Pipeline update and final results for the year ended 31 January 2024

London, UK, 6 June 2024 - e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced its audited results for the year ended 31 January 2024 and provided an update on recent pipeline progress.

“The 2023/24 financial year was an important time for e-therapeutics, marking the beginning of a period of effective execution in advancing our therapeutic pipeline. During the year we delivered solid pipeline progress, generating positive preclinical proof-of-concept data for four GalOmic™ RNAi assets discovered in-house.” commented Ali Mortazavi, Chief Executive Officer

“I am pleased to say we have continued on this impressive trajectory during the first months of the new financial year, progression of ETX-258 through proof-of-concept studies in heart failure, and the addition of a new MASH program, ETX-394. The promising datasets we are generating on our pipeline programs provide the ultimate validation for our innovative AI-enhanced approach to the R&D process and showcase the strength of our enabling platforms HepNet™ and GalOmic™.”

Recent pipeline progress

  • IND-enabling studies initiated on ETX-312 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), with an IND submission anticipated during 2025
  • ETX-258 for the treatment of heart failure progressing through proof-of-concept studies
  • New program added to our pipeline: ETX-394 for the treatment of MASH. ETX-394 targets different disease biology to ETX-312, silencing another novel and differentiated target gene. Preclinical proof-of-concept studies are underway.

FY2023/24 operational highlights

  • Completed positive preclinical proof-of-concept data packages for four GalOmic™ assets
  • Selected two assets for progression towards the clinic: ETX-312 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and ETX-407 for dry age-related macular degeneration
  • Expansion of data on metabolic dysfunction and associated fatty liver disease through strategic collaboration with Arcturis Data (Arcturis) to integrate Arcturis’ high quality, clinically rich real-world evidence (RWE) patient data within HepNet™
  • Generation of a wealth of in-house experimental data significantly expanding the proprietary datasets that feed into HepNet™
  • Advanced projects developing and implementing large language models (LLMs) across ETX processes and systems, further enhancing computational capabilities
  • Continued to leverage our HepNet™ computational platform, including network analytics, a hepatocyte-specific knowledge graph, and predictive short interfering RNA (siRNA) construct design capabilities to rapidly develop life-transforming RNAi therapies
  • Last near-term milestone successfully achieved in collaboration with iTeos Therapeutics in immuno-oncology, resulting in an additional payment to the Company and further validating its computational approach to identifying novel targets
  • Sustained intellectual property (IP) activity with priority patent applications filed on nine further inventions, and international patent applications filed for eight inventions arising from the Company’s proprietary GalNAc-siRNA technology, GalOmic™
  • Continued investment in leading industry talent, including new hires on the East Coast of the USA, a major biotech hub
  • Effective 20 September 2023, Timothy Bretherton assumed the role of Chief Financial Officer (CFO, non-Board)

Post period operational highlights

  • Successful fundraise of £28.9 million announced in April 2024 by way of a subscription by funds managed by M&G Investment Management Limited and Richard Griffiths, both existing shareholders of the Company
  • Completed cancellation of admission of our Ordinary Shares to trading on AIM as of 9 May 2024
  • Strengthened the Board of Directors with the appointment of Lord David Prior as Chair, as of 23 May 2024

FY2023/24 financial highlights

  •  Cash and short-term investment bank deposits at 31 January 2024 of £20.7 million (2023: £31.7 million)
  • Revenues of £0.3 million (2023: £0.5 million)
  • R&D spend of £10.2 million (2023: £7.2 million)
  • Operating loss of £13.8 million (2023: £10.2 million)
  • Loss for the year of £11.2 million (2023: £8.3 million)
  • £1.9 million R&D tax credit receivable (2023: £1.5 million)

Please find additional information in the e-therapeutics’ Annual Report and Accounts 2024, which includes the Notice of Annual General Meeting. This was published today on the Company’s website at www.etherapeutics.co.uk/investors/financials-company-documents/ and will be posted to shareholders next week.

The Annual General Meeting will be held at 12:30 p.m. on Tuesday, 16 July 2024, at the Company's registered office at 4 Kingdom Street, Paddington, London W2 6BD.



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1919909  06-Jun-2024 

fncls.ssp?fn=show_t_gif&application_id=1919909&application_name=news&site_id=boersennews_de~~~d41e2cc8-bdcb-47ba-bb51-c77a04513666
Kommentare (0) ... diskutiere mit.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer